| http://dbpedia.org/ontology/abstract
|
Sirna Therapeutics, Inc. was a San Francis … Sirna Therapeutics, Inc. was a San Francisco, California based biotechnology company that explored the use of RNA interference in human disease therapy. Sirna's development pipeline included several small interfering RNA (siRNA) drugs, thought to stably silence the expression of specific disease-related genes. Sirna's clinical trial of an siRNA-based treatment for age-related macular degeneration was the first such trial for an siRNA drug. Sirna Therapeutics was acquired by Merck & Co. in 2006, the cash transaction deal was worth $1.1 billion.h transaction deal was worth $1.1 billion.
|
| http://dbpedia.org/ontology/wikiPageExternalLink
|
https://web.archive.org/%2A/http:/www.sirna.com +
|
| http://dbpedia.org/ontology/wikiPageID
|
9457734
|
| http://dbpedia.org/ontology/wikiPageLength
|
4156
|
| http://dbpedia.org/ontology/wikiPageRevisionID
|
994523081
|
| http://dbpedia.org/ontology/wikiPageWikiLink
|
http://dbpedia.org/resource/Boulder%2C_Colorado +
, http://dbpedia.org/resource/Gene_silencing +
, http://dbpedia.org/resource/Gavin_Newsom +
, http://dbpedia.org/resource/RNA_interference +
, http://dbpedia.org/resource/San_Francisco +
, http://dbpedia.org/resource/Cambridge%2C_Massachusetts +
, http://dbpedia.org/resource/Biotechnology +
, http://dbpedia.org/resource/San_Diego%2C_California +
, http://dbpedia.org/resource/Gene_expression +
, http://dbpedia.org/resource/Disease +
, http://dbpedia.org/resource/Category:Biotechnology_companies_of_the_United_States +
, http://dbpedia.org/resource/Clinical_trial +
, http://dbpedia.org/resource/Drug +
, http://dbpedia.org/resource/California +
, http://dbpedia.org/resource/Category:Merck_&_Co. +
, http://dbpedia.org/resource/Macular_degeneration +
, http://dbpedia.org/resource/Mayor_of_San_Francisco +
, http://dbpedia.org/resource/Category:Companies_based_in_San_Francisco +
, http://dbpedia.org/resource/Merck_&_Co. +
, http://dbpedia.org/resource/Category:2006_mergers_and_acquisitions +
, http://dbpedia.org/resource/Category:Health_care_companies_based_in_California +
, http://dbpedia.org/resource/Small_interfering_RNA +
|
| http://dbpedia.org/property/wikiPageUsesTemplate
|
http://dbpedia.org/resource/Template:Reflist +
, http://dbpedia.org/resource/Template:Short_description +
, http://dbpedia.org/resource/Template:Portal +
|
| http://purl.org/dc/terms/subject
|
http://dbpedia.org/resource/Category:Health_care_companies_based_in_California +
, http://dbpedia.org/resource/Category:Merck_&_Co. +
, http://dbpedia.org/resource/Category:Biotechnology_companies_of_the_United_States +
, http://dbpedia.org/resource/Category:2006_mergers_and_acquisitions +
, http://dbpedia.org/resource/Category:Companies_based_in_San_Francisco +
|
| http://www.w3.org/ns/prov#wasDerivedFrom
|
http://en.wikipedia.org/wiki/Sirna_Therapeutics?oldid=994523081&ns=0 +
|
| http://xmlns.com/foaf/0.1/isPrimaryTopicOf
|
http://en.wikipedia.org/wiki/Sirna_Therapeutics +
|
| owl:sameAs |
http://rdf.freebase.com/ns/m.0289nf8 +
, http://yago-knowledge.org/resource/Sirna_Therapeutics +
, http://dbpedia.org/resource/Sirna_Therapeutics +
, http://www.wikidata.org/entity/Q7530516 +
, https://global.dbpedia.org/id/4v3dt +
|
| rdf:type |
http://dbpedia.org/class/yago/YagoPermanentlyLocatedEntity +
, http://dbpedia.org/class/yago/Institution108053576 +
, http://dbpedia.org/class/yago/WikicatCompaniesBasedInSanFrancisco%2CCalifornia +
, http://dbpedia.org/class/yago/Group100031264 +
, http://dbpedia.org/class/yago/SocialGroup107950920 +
, http://dbpedia.org/class/yago/Abstraction100002137 +
, http://dbpedia.org/class/yago/Organization108008335 +
, http://dbpedia.org/class/yago/Company108058098 +
, http://dbpedia.org/class/yago/YagoLegalActorGeo +
, http://dbpedia.org/class/yago/YagoLegalActor +
|
| rdfs:comment |
Sirna Therapeutics, Inc. was a San Francis … Sirna Therapeutics, Inc. was a San Francisco, California based biotechnology company that explored the use of RNA interference in human disease therapy. Sirna's development pipeline included several small interfering RNA (siRNA) drugs, thought to stably silence the expression of specific disease-related genes. Sirna's clinical trial of an siRNA-based treatment for age-related macular degeneration was the first such trial for an siRNA drug. Sirna Therapeutics was acquired by Merck & Co. in 2006, the cash transaction deal was worth $1.1 billion.h transaction deal was worth $1.1 billion.
|
| rdfs:label |
Sirna Therapeutics
|
